
Priavoid’s Alzheimer’s drug misses Phase 2 efficacy endpoint
German biotech Priavoid has missed the primary efficacy endpoint in a Phase 2 trial of its oral Alzheimer’s drug PRI-002. However, the company reported encouraging signs of cognitive benefit in longer-term exploratory analyses, leaving the future of its experimental treatment open.
How it works: PRI-002 is an all-D-peptide, a molecule composed of synthetic peptides built from the mirror-image forms of naturally occurring amino acids. The drug is designed to bind soluble amyloid-beta oligomers, small protein clusters believed to contribute to neuronal damage in Alzheimer’s disease, and break them apart into less harmful individual molecules.
This differs from approved antibodies such as Leqembi and Kisunla, which target amyloid deposits and are administered intravenously.
Zoom in: The randomized, placebo-controlled PRImus-AD trial enrolled 304 patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease across six European countries.
Patients received either 300 mg or 600 mg of PRI-002 daily, or placebo, for 48 to 96 weeks. The study met its primary safety endpoint but failed to show a significant benefit on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), which measures cognitive and functional decline, at Week 48.
The positive signal: Priavoid reported that the treatment’s effects became more pronounced with longer follow-up.
- At Week 72, PRI-002 was associated with a 35.9% slowing of cognitive decline on the ADAS-Cog13 scale in the per-protocol population, reaching statistical significance (p=0.022).
- In the broader modified intention-to-treat population, the reduction was 26.7%, but the difference was not statistically significant (p=0.102).
- Measures of patients’ ability to perform daily activities also favored PRI-002, although these differences did not reach statistical significance.
Yes, but: The statistically significant result came from an exploratory analysis involving just 144 patients who followed the study protocol and reached Week 72. The broader modified intention-to-treat population did not show a statistically significant benefit. These findings therefore cannot compensate for the missed primary efficacy endpoint.
The benchmark: Approved Alzheimer’s antibodies have shown stronger evidence of clinical benefit. Eisai and Biogen’s Leqembi slowed cognitive and functional decline by 27% on the CDR-SB scale over 18 months, while Eli Lilly’s Kisunla achieved a 29% reduction over 76 weeks. Both results were statistically significant in large Phase 3 trials.
Priavoid reported a 12% slowing on the same scale at Week 72 in its broader modified intention-to-treat population, but the difference was not statistically significant. Although the studies cannot be compared directly, the contrast highlights how much clinical evidence PRI-002 still needs to establish its efficacy.
Safety: Priavoid described the treatment as well tolerated. Amyloid-related imaging abnormalities involving brain swelling (ARIA-E) occurred in 2% of patients receiving 300 mg, none receiving 600 mg and 1% receiving placebo. ARIA involving bleeding (ARIA-H) was reported in 8%, 11.7% and 5% of patients, respectively.
What’s next: The Düsseldorf-based company, a spinout of Heinrich Heine University Düsseldorf and Forschungszentrum Jülich, plans to present the complete dataset, including additional biomarker analyses, in 2027. Priavoid is now evaluating whether the findings justify another clinical study and how that study should be designed.




